

**NHS National framework agreement - Home Delivery Service Pulmonary Hypertension**

**Offer reference number: CM/MSR/17/5557**

**Period of framework agreement: 1 June 2024 to 31 May 2026 with option(s) to extend for up to a total period of 24 months.**

**Targeted therapies for pulmonary arterial hypertension** (for information only)

For information only: list of drugs currently commissioned and drugs that may be available to commission during the life of the framework.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **DRUG NAME** | **NICE APPROVED ENGLAND** | **NHS England Commissioned** | **Not yet approved/commissioned but decision expected in life of Framework** | **Comments** |
| AMBRISENTAN | Not appraised | Y |  | Oral. Generic available |
| BOSENTAN | Not appraised | Y |  | Oral. Generic available |
| EPOPROSTENOL | Not appraised | Y |  | Continuous infusion |
| ILOPROST | Not appraised | Y |  | Inhaled and infusion. Managed access scheme |
| MACITENTAN | Not appraised | Y |  | Oral |
| RIOCIGUAT | Not appraised | Y |  | Oral |
| SELEXIPAG | Not appraised | Y |  | Oral |
| SILDENAFIL | Not appraised | Y |  | Oral. Generic available |
| TADALAFIL | Not appraised | Y |  | Oral. Generic available |
| TREPROSTINIL SODIUM | Not appraised | N |  | Continuous infusion. Managed access scheme.At present, only legacy patients are funded for ongoing treatment with treprostinil but NHS England is considering a policy proposal for routine funding, which will increase use. |
| SOTATERCEPT | In development (ID6163) | N | Y | 3 weekly injection |